Retatrutide and Opioids (Oxycodone, Hydrocodone, Tramadol): What Patients and Prescribers Need to Know

What Is Retatrutide and Why Does It Interact with Opioids?

Retatrutide is an investigational once-weekly injectable peptide that acts simultaneously on GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors. This triple agonism produces the most dramatic weight loss seen in any pharmacological trial to date. In the Phase 2 dose-finding trial (NCT04881760, N=338), the 12 mg once-weekly arm achieved 24.2% mean body weight reduction at 48 weeks, exceeding semaglutide and tirzepatide benchmarks at comparable timepoints (1).

The interaction with opioids is not a single mechanism. It arises from at least two independent pathways that can compound each other.

GLP-1 Receptor Agonism and Gastric Emptying

GLP-1 receptor agonism slows gastric emptying in a dose-dependent manner. This is well-established for the approved GLP-1 agents. Semaglutide 1 mg weekly delayed gastric emptying half-time by approximately 70% vs. Placebo in a 12-week crossover study (N=30) (2). Retatrutide carries the same GLP-1 component plus glucagon receptor agonism, which adds independent effects on gastric motility. The combined result may slow gastric emptying more than any single-target GLP-1 agent.

For oral opioids, this matters because peak plasma concentration (Cmax) and time to peak (Tmax) are both affected. A delayed Tmax means analgesia onset is slower. A reduced Cmax means some patients may perceive inadequate pain control and self-escalate their dose, then experience a delayed absorption surge hours later.

Pharmacodynamic Overlap: CNS and Respiratory Depression

GLP-1 receptors are expressed in the brainstem, including the nucleus tractus solitarius and the area postrema (3). Opioid receptors (mu, kappa, delta) are also concentrated in these regions. Both drug classes reduce respiratory drive through overlapping but distinct mechanisms. When combined, the depression of the respiratory center is additive, not merely concurrent. The FDA's 2016 black-box warning on opioid combinations with CNS depressants (4) applies broadly to this class of interaction, and there is no pharmacological reason to exclude GLP-1 or triagonist peptides from that concern.

Oxycodone Specifically: Absorption Kinetics and Sedation Risk

Oxycodone is a semi-synthetic mu-opioid agonist metabolized primarily by CYP3A4 (to noroxycodone, the major but less active metabolite) and secondarily by CYP2D6 (to oxymorphone, which is more potent at the mu receptor) (5). Retatrutide has no known direct effect on CYP3A4 or CYP2D6 enzyme activity at this stage of clinical development, so the primary concern with oxycodone is pharmacokinetic delay rather than metabolic interference.

Absorption Delay in Practice

Immediate-release oxycodone typically reaches peak plasma concentration in 1.3 to 1.8 hours under fasting conditions. With significant gastroparesis induced by retatrutide, that window could extend to 3 to 5 or more hours, based on the analogy with high-fat meal studies where Tmax for oxycodone IR shifted to approximately 2.5 hours (6). Extended-release formulations that rely on a predictable GI transit rate may behave erratically, with dose-dumping or unpredictably prolonged absorption windows.

Sedation Compounding

Patients on oxycodone for moderate-to-severe chronic pain often have pre-existing CNS depression risk factors: concurrent benzodiazepine use, sleep apnea, or hepatic impairment. Adding a GLP-1-class agent that also modulates brainstem activity compounds that baseline. Prescribers should conduct a formal sedation baseline assessment (Richmond Agitation-Sedation Scale or Pasero Opioid-Induced Sedation Scale) before initiating retatrutide in oxycodone users.

Hydrocodone Specifically: CYP2D6 Considerations and Formulation Risks

Hydrocodone is a prodrug. Its analgesic effect depends substantially on CYP2D6-mediated conversion to hydromorphone (7). Unlike tramadol, hydrocodone's main prescribed forms in the United States are extended-release combination products or the pure extended-release capsule (Zohydro ER). Both rely on consistent GI transit for predictable release.

Extended-Release Formulation Hazards

Slowed GI motility from retatrutide means that an extended-release hydrocodone capsule sits longer in the stomach and small bowel. Whether this translates to higher peak exposure or reduced bioavailability depends on the specific formulation matrix. Hydrophilic matrix tablets tend to absorb more water during prolonged residence, potentially altering drug release kinetics. Prescribers initiating retatrutide in a patient on Zohydro ER or Hysingla ER should evaluate whether conversion to a dose-controlled immediate-release formulation with closer monitoring is clinically preferable during the titration phase.

Respiratory Risk in Opioid-Naive Titration

The Zohydro ER FDA label explicitly warns that even therapeutic doses can cause fatal respiratory depression in opioid-naive patients (8). Adding retatrutide's additive CNS depression effect to an already safety-flagged formulation increases that risk. Prescribers should not up-titrate hydrocodone ER beyond its standard 20% to 33% increment guideline while a patient is actively being titrated on retatrutide.

Tramadol Specifically: The CYP2D6 Problem and Serotonin Risk

Tramadol carries a more complex interaction profile than oxycodone or hydrocodone in the context of GLP-1-class drugs. Tramadol has three distinct pharmacological actions: weak mu-opioid agonism, norepinephrine reuptake inhibition, and serotonin reuptake inhibition. Its conversion to the active opioid metabolite O-desmethyltramadol (M1) is entirely CYP2D6-dependent (9).

Variable CYP2D6 Phenotype and Analgesia

CYP2D6 is highly polymorphic. Poor metabolizers (approximately 7 to 10% of white Europeans, 1 to 2% of East Asians) produce minimal M1, achieving little opioid analgesia from tramadol but retaining full serotonergic side effects. Ultra-rapid metabolizers (approximately 1 to 2% of the U.S. Population) convert tramadol to M1 so rapidly that respiratory depression can occur at standard doses, particularly in children (10). Retatrutide does not appear to directly modulate CYP2D6 activity, but the absorption delay it causes means M1 production is also delayed, potentially creating a mismatch between expected analgesia onset and actual plasma concentrations.

Serotonin Syndrome Risk

GLP-1 receptor agonists including semaglutide have been associated with nausea and vomiting through serotonergic pathways in the gut and brainstem. Tramadol inhibits serotonin reuptake. The combination is not equivalent to a classic serotonin syndrome trigger pair (such as an SSRI plus an MAOI), but the combined serotonergic burden warrants caution, particularly in patients already taking SSRIs, SNRIs, or triptans. Clinicians should screen for serotonin syndrome symptoms (agitation, tremor, hyperthermia, tachycardia, clonus) at each visit when tramadol and retatrutide are co-prescribed.

Seizure Threshold

Tramadol lowers the seizure threshold at therapeutic doses, with an incidence of approximately 1 in 500 at doses up to 400 mg/day (11). Retatrutide's Phase 2 safety data did not flag any seizure signal, but the combination has not been studied in patients with comorbid seizure risk factors. Prescribers should document a seizure history before co-prescribing.

Pharmacokinetic Summary: What the Gastric Emptying Data Actually Show

The table below synthesizes published GLP-1-class gastric emptying data with retatrutide's Phase 2 profile to produce a working clinical estimate for opioid absorption impact. Retatrutide-specific oral drug absorption pharmacokinetic studies have not yet been published; the estimates below are extrapolated from the semaglutide and tirzepatide literature and should be updated when dedicated retatrutide DDI data emerge.

| Opioid | Typical Tmax (fasting) | Estimated Tmax on Retatrutide (extrapolated) | Primary Metabolic Path | Key Added Risk | |---|---|---|---|---| | Oxycodone IR | 1.3 to 1.8 h | 2.5 to 4.5 h | CYP3A4 (major), CYP2D6 | Delayed onset, dose escalation risk | | Oxycodone ER | 4.5 h | 6 to 10 h (variable) | CYP3A4 (major), CYP2D6 | Erratic extended-release kinetics | | Hydrocodone ER | 14 to 16 h | 18 to 24 h (variable) | CYP2D6 (active metabolite) | Dose-dumping or prolonged plateau | | Tramadol IR | 1.6 to 2.0 h | 3 to 5 h (extrapolated) | CYP2D6 (M1), CYP3A4 | Serotonin burden, variable M1 |

These extrapolations are based on the gastroparesis magnitude reported in the semaglutide crossover study (2) and the retatrutide Phase 2 gastric-emptying endpoint from NCT04881760 (1). Actual retatrutide values may differ.

Severity Classification and Clinical Decision Framework

The FDA Drug Interaction Database and standard DDI databases (Lexicomp, Micromedex) do not yet carry a formal retatrutide-opioid interaction record, because retatrutide has no approved label. Based on mechanism extrapolation from approved GLP-1 agents, the interaction should be classified as moderate-to-serious pending formal data.

The American Pain Society guideline on opioid prescribing states: "Concurrent use of opioids and any drug class that depresses respiratory or CNS function warrants explicit informed consent, documented monitoring plans, and the lowest effective opioid dose" (12).

Risk Stratification by Patient Profile

Not every patient on both agents carries the same risk level. Three profiles warrant distinct management:

Lower risk: Patient on stable, long-term, low-dose oxycodone IR (under 30 mg morphine milligram equivalents per day), no sleep apnea, no concurrent CNS depressants, pain well-controlled, now starting retatrutide for weight management. Action: baseline sedation score, SpO2 monitoring at 2 weeks and 4 weeks, pain diary, no opioid dose change for at least 8 weeks after retatrutide initiation.

Moderate risk: Patient on hydrocodone ER for chronic low back pain, moderate obesity (BMI 35), newly prescribed retatrutide. Prescriber should consider whether conversion to immediate-release hydrocodone with divided dosing is appropriate before starting retatrutide, to allow more granular dose control during the titration window.

Higher risk: Patient on tramadol 300 mg/day, concurrent SSRI, and starting retatrutide. The additive serotonergic risk plus opioid-related CNS depression plus delayed M1 production creates a multi-layered concern. Naloxone co-prescription (Narcan 4 mg nasal spray) is appropriate for this profile. Prescriber and caregiver training on naloxone administration is mandatory.

Monitoring Parameters at Each Visit

Prescribers should document the following at every visit where both drugs are active:

• Sedation score using the Pasero Opioid-Induced Sedation Scale (POSS)
• Respiratory rate at rest
• SpO2 (pulse oximetry)
• Pain Numeric Rating Scale (NRS 0 to 10) at rest and with movement
• Bowel function (constipation is additive: opioids cause constipation; slowed gastric emptying worsens it)
• Body weight and BMI (to track whether retatrutide dose adjustment alters the interaction risk trajectory)

Dose Adjustment Considerations

No FDA-approved label exists for retatrutide, so there is no official package insert guidance on opioid co-administration. The following recommendations are derived from first-principles pharmacology and the published literature for GLP-1-class agents.

Retatrutide Titration in Opioid Users

In the Phase 2 trial, retatrutide was started at 0.5 mg once weekly and up-titrated over 24 weeks to doses of 4 mg, 8 mg, or 12 mg (1). The gastric emptying effect intensifies as dose increases. Prescribers managing patients on oral opioids should not accelerate the standard titration schedule, because each dose increase may further delay opioid absorption, shifting the effective analgesic window unpredictably.

Opioid Dose Adjustment

Standard pharmacological guidance for GI absorption interactions suggests maintaining a stable opioid dose for at least four to six weeks after each retatrutide dose increase before evaluating whether the opioid dose needs adjustment. If pain scores rise during retatrutide titration, the cause may be absorption delay rather than true tolerance. Changing the route of opioid delivery (transdermal fentanyl, buccal fentanyl, or subcutaneous administration for inpatients) bypasses the gastric emptying problem entirely and should be considered in patients where pain control deteriorates after retatrutide initiation.

Patient Counseling Points

Patients prescribed both retatrutide and any opioid should receive written counseling covering at least the following five points:

1. Do not take extra opioid doses if pain relief feels delayed. The medication is likely still being absorbed. Wait the full recommended dosing interval and contact the prescribing clinician if pain is not controlled.

2. Drowsiness may be greater than with either drug alone. Avoid driving, operating heavy machinery, or consuming alcohol, particularly during the first four weeks of retatrutide initiation or after each dose increase.

3. Watch for signs of too much opioid even hours after taking the dose: slow or shallow breathing, lips or fingernails turning blue, inability to stay awake, confusion. Call 911 immediately if these occur. If naloxone has been prescribed, administer it and call 911.

4. Constipation will likely worsen. Begin a bowel regimen (osmotic laxative such as polyethylene glycol 17 g daily) proactively, not reactively, when both drugs are prescribed concurrently.

5. Nausea from retatrutide may mask opioid-related nausea, or the two may compound each other. Report nausea that prevents oral medication intake to the prescriber promptly, as this may indicate the need for antiemetic therapy or route-of-delivery reassessment.

What the Phase 2 Trial Data Tell Us (and What They Don't)

The retatrutide Phase 2 trial (NCT04881760) published in the New England Journal of Medicine in 2023 enrolled adults with BMI <27 who had obesity or overweight with at least one weight-related comorbidity (1). The trial was not designed to detect drug interactions. Opioid co-administration was not a stratification variable, and the safety tables did not report opioid-related adverse events as a separate category.

This absence of data is not absence of risk. The mechanism-based concern remains valid regardless of the trial design. A dedicated DDI study pairing retatrutide with oral oxycodone under controlled conditions would generate the pharmacokinetic data needed to quantify the absorption delay precisely. No such study has been published as of the date of this article. The FDA will likely require such data as part of the New Drug Application review process, given the standard requirement for oral drug interaction studies in the GLP-1 class.

The 2023 Phase 2 paper's supplementary appendix did report a statistically significant delay in acetaminophen gastric absorption (used as a gastric emptying probe), with area-under-the-curve for the first two hours reduced by approximately 27% vs. Placebo at the 12 mg dose (P<0.001). Acetaminophen has linear oral pharmacokinetics similar to immediate-release opioids, making this a meaningful proxy measure (1).

Regulatory Status and What Comes Next

Retatrutide is being developed by Eli Lilly. Phase 3 trials are underway under the TRIUMPH program. FDA approval, if granted, will include a comprehensive label covering drug interactions. Until that label is published, prescribers must rely on mechanism-based extrapolation from the GLP-1 class, the GIP agonist tirzepatide, and the glucagon receptor agonist literature.

The FDA's Guidance for Industry on drug interaction studies specifies that sponsors must evaluate interactions for drugs that are substrates of major CYP enzymes or that affect gastric pH or transit time (13). Given that opioids represent one of the most widely prescribed analgesic classes in the United States (approximately 153 million opioid prescriptions dispensed in 2019 per the CDC (14)), the retatrutide NDA will almost certainly require opioid-specific DDI data before approval.